Detalhe da pesquisa
1.
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol
; 204(2): 525-533, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905734
2.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Lancet Oncol
; 24(8): 913-924, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414060
3.
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Cancer Immunol Immunother
; 72(4): 827-840, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36083313
4.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
Am J Hematol
; 97(6): 731-739, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35253928
5.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Mol Ther
; 29(2): 636-644, 2021 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010231
6.
Alternative to In Vivo Tests During the COVID-19 Pandemic: Multiple Allergen Simultaneous Tests as a Useful First Screening.
Clin Lab
; 67(12)2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910432
7.
Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
Allergol Immunopathol (Madr)
; 49(1): 118-127, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528939
8.
Vaccines for Non-Viral Cancer Prevention.
Int J Mol Sci
; 22(20)2021 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34681560
9.
Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?
Pediatr Allergy Immunol
; 33(10): e13860, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282139
10.
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Clin Cancer Res
; 30(10): 2085-2096, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38466644
11.
Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing.
Front Immunol
; 13: 1005457, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36238283
12.
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation.
Front Oncol
; 12: 828471, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35174095
13.
Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients.
Free Neuropathol
; 32022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284165
14.
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
Sci Adv
; 8(39): eabo0514, 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179026
15.
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
J Immunother Cancer
; 9(12)2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34876408
16.
CART manufacturing process and reasons for academy-pharma collaboration.
Immunol Lett
; 217: 39-48, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669547
17.
Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations.
Front Immunol
; 10: 769, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31031763
18.
Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.
Front Immunol
; 8: 299, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28396659
19.
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.
J Immunother Cancer
; 9(12)2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907029